MPN Congress — 12th International Congress on Myeloproliferative Neoplasms

Since the inaugural Congress in 2001, this meeting has become the premier forum for discussion on the latest advances in myeloproliferative neoplasms (MPNs). This year, the Congress will focus on timely topics of interest to hematologists and oncologists who treat patients with these rare disorders. The Congress program format will utilize case presentations to highlight the essential features of MPN pathophysiology, diagnosis and management, as well as the roles of next generation sequencing and the MPN driver mutation and allele burden in clinical decision making. In addition to defining the role of pegylated interferon and its long-acting derivatives in MPN therapy, the role of immunotherapy in the MPNs and novel agents for MPN treatment will be reviewed. New this year will be a discussion of the management of accelerated and blast phase MPN, patient selection for bone marrow transplantation, and how to integrate MPN patient symptom scores with therapeutic planning. The program features a world class faculty and highly interactive sessions designed to engage participants and provide a state-of-the-art learning experience.

Topics: myeloproliferative neoplasms, MPN, polycythemia vera, PV, essential thrombocythemia, ET, myelofibrosis, MF, PMF, Chronic myeloid leukemia, CML, CNL, mastocytosis, hematopoiesis